BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34390327)

  • 1. Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact.
    Oelschlaegel U; Oelschlaeger L; von Bonin M; Kramer M; Sockel K; Mohr B; Wagenfuehr L; Kroschinsky F; Bornhaeuser M; Platzbecker U
    Cytometry B Clin Cytom; 2023 Mar; 104(2):141-150. PubMed ID: 34390327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India.
    Dhingra G; Dass J; Arya V; Gupta N; Saraf A; Langer S; Aggarwal S; Kotwal J; Bhargava M
    Indian J Med Res; 2020 Sep; 152(3):254-262. PubMed ID: 33107485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
    Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
    Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
    Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
    Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes.
    Gardikas N; Vikentiou M; Konsta E; Kontos CK; Papageorgiou SG; Spathis A; Bazani E; Bouchla A; Kapsimali V; Psarra K; Foukas P; Dimitriadis G; Pappa V
    Cytometry B Clin Cytom; 2019 Jan; 96(1):73-82. PubMed ID: 30334347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study.
    Chauhan R; Singh J; Sharma C; Dange P; Chopra A; Mahapatra M; Pati H
    Leuk Res; 2021 Aug; 107():106651. PubMed ID: 34218155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
    Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
    Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Multicolor Flow Cytometry Scoring System for the Diagnosis and Prognostic Stratification of Myelodysplastic Syndromes.
    Lai B; Chen Y; Li M; Ye G; Luo H; Zhong Y; Guo X
    Clin Lab; 2022 Sep; 68(9):. PubMed ID: 36125138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes.
    Kárai B; Bedekovics J; Miltényi Z; Gergely L; Szerafin L; Ujfalusi A; Kappelmayer J; Hevessy Z
    Int J Lab Hematol; 2017 Dec; 39(6):577-584. PubMed ID: 28625017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.
    Xu F; Li X; Chang CK; Guo J; Wu LY; He Q; Zhang Z; Zhu Y; Gu SC; Shi WH; Song LX; Su JY; Zhou LY; Zhang X; Wu D
    PLoS One; 2014; 9(2):e88706. PubMed ID: 24558415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
    Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
    Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.
    Verigou E; Lampropoulou P; Smyrni N; Kolliopoulou G; Sakellaropoulos G; Starakis I; Zikos P; Solomou E; Symeonidis A; Karakantza M
    Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):148-61. PubMed ID: 26126819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
    Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
    Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
    Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
    Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
    van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
    Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.
    Wells DA; Benesch M; Loken MR; Vallejo C; Myerson D; Leisenring WM; Deeg HJ
    Blood; 2003 Jul; 102(1):394-403. PubMed ID: 12649150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
    Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
    Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes.
    Davydova YO; Parovichnikova EN; Galtseva IV; Kokhno AV; Dvirnyk VN; Kovrigina AM; Obukhova TN; Kapranov NM; Nikiforova KA; Glinkina SA; Troitskaya VV; Mikhailova EA; Fidarova ZT; Moiseeva TN; Lukina EA; Tsvetaeva NV; Nikulina OF; Kuzmina LA; Savchenko VG
    Cytometry B Clin Cytom; 2021 May; 100(3):312-321. PubMed ID: 33052634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.
    Wu A; Gao P; Wu N; Shi C; Huang Z; Rong C; Sun Y; Sheng L; Ouyang G; Mu Q
    BMC Cancer; 2021 May; 21(1):546. PubMed ID: 33985456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.